New ALS Treatment Improves Survival and Quality of Life
新型漸凍症治療方案能延長患者生存期並提升生活品質
The fight against Amyotrophic Lateral Sclerosis (ALS) is entering a new era of precision medicine.
對抗肌萎縮性脊髓側索硬化症（ALS）的鬥爭正進入精準醫療的新時代。
While the search for a universal cure continues, researchers are finding success by focusing on specific genetic drivers of the disease.
儘管尋找廣泛療法的探索仍在持續，研究人員透過專注於該疾病的特定遺傳驅動因素而獲得成功。
A major breakthrough is Tofersen, a treatment specifically designed for patients with a mutation in the SOD1 gene.
一項重大突破是Tofersen，這是專為SOD1基因突變患者設計的治療藥物。
Data indicates that early initiation of Tofersen significantly slows the progression of physical and respiratory decline, helping many patients maintain their independence for longer.
數據顯示，及早開始使用Tofersen可顯著減緩身體與呼吸功能下降的進程，協助許多患者更長時間維持獨立生活。
This success underscores the importance of precision medicine over broad, one-size-fits-all treatments.
這種成功凸顯了精準醫療相較於廣泛且一體適用之治療的重要性。
